CA
DNTH icon

CoreCap Advisors’s Dianthus Therapeutics DNTH Stock Holding History

CoreCap Advisors’s Portfolio DNTH Stock Details DNTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-11
Closed -$200 – 2897
2025
Q1 		$200 Buy
+11
New +$242 ﹤0.01% 2979

Other funds holding DNTH

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CoreCap Advisors's DNTH Position: Q2 2025 in Review

CoreCap Advisors sold out of Dianthus Therapeutics (DNTH) in Q2 2025, closing a stake of 11 shares — an estimated $200 sold.

CoreCap Advisors first reported a position in DNTH in Q1 2025 and held it in 1 quarter. The position peaked at $200 in Q1 2025. 102 funds tracked by Wall St. Rank hold DNTH as of Q2 2025.

  • CoreCap Advisors reported no remaining Dianthus Therapeutics position as of Q2 2025 after selling out during the quarter.
  • CoreCap Advisors sold 11 Dianthus Therapeutics shares in Q2 2025, an estimated $200.
  • CoreCap Advisors first reported a position in Dianthus Therapeutics in Q1 2025 and held it in 1 quarter.
  • CoreCap Advisors's Dianthus Therapeutics position peaked at $200 in Q1 2025.
  • 102 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q2 2025.

Based on CoreCap Advisors's 13F filing for Q2 2025, filed 14 Aug 2025.